FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1605753053> ?p ?o ?g. }

• W1605753053 endingPage "16811" @default.
• W1605753053 startingPage "16797" @default.
• W1605753053 abstract "Galectin-9 (gal-9) is a multifunctional β-galactoside-binding lectin, frequently released in the extracellular medium, where it acts as a pleiotropic immune modulator. Despite its overall immunosuppressive effects, a recent study has reported bimodal action of gal-9 on human resting blood T cells with apoptosis occurring in the majority of them, followed by a wave of activation and expansion of Th1 cells in the surviving population. Our knowledge of the signaling events triggered by exogenous gal-9 in T cells remains limited. One of these events is cytosolic calcium (Ca2+) release reported in some murine and human T cells. The aim of this study was to investigate the contribution of Ca2+ mobilization to apoptotic and nonapoptotic effects of exogenous gal-9 in human T cells. We found that the T cell receptor (TCR)-CD3 complex and the Lck kinase were required for Ca2+ mobilization but not for apoptosis induction in Jurkat cells. These data were confirmed in human CD4+ T cells from peripheral blood as follows: a specific Lck chemical inhibitor abrogated Ca2+ mobilization but not apoptosis induction. Moreover, Lck activity was also required for the production of Th1-type cytokines, i.e. interleukin-2 and interferon-γ, which resulted from gal-9 stimulation in peripheral CD4+ T cells. These findings indicate that gal-9 acts on T cells by two distinct pathways as follows: one mimicking antigen-specific activation of the TCR with a mandatory contribution of proximal elements of the TCR complex, especially Lck, and another resulting in apoptosis that is independent of this complex. Galectin-9 (gal-9) is a multifunctional β-galactoside-binding lectin, frequently released in the extracellular medium, where it acts as a pleiotropic immune modulator. Despite its overall immunosuppressive effects, a recent study has reported bimodal action of gal-9 on human resting blood T cells with apoptosis occurring in the majority of them, followed by a wave of activation and expansion of Th1 cells in the surviving population. Our knowledge of the signaling events triggered by exogenous gal-9 in T cells remains limited. One of these events is cytosolic calcium (Ca2+) release reported in some murine and human T cells. The aim of this study was to investigate the contribution of Ca2+ mobilization to apoptotic and nonapoptotic effects of exogenous gal-9 in human T cells. We found that the T cell receptor (TCR)-CD3 complex and the Lck kinase were required for Ca2+ mobilization but not for apoptosis induction in Jurkat cells. These data were confirmed in human CD4+ T cells from peripheral blood as follows: a specific Lck chemical inhibitor abrogated Ca2+ mobilization but not apoptosis induction. Moreover, Lck activity was also required for the production of Th1-type cytokines, i.e. interleukin-2 and interferon-γ, which resulted from gal-9 stimulation in peripheral CD4+ T cells. These findings indicate that gal-9 acts on T cells by two distinct pathways as follows: one mimicking antigen-specific activation of the TCR with a mandatory contribution of proximal elements of the TCR complex, especially Lck, and another resulting in apoptosis that is independent of this complex." @default.
• W1605753053 created "2016-06-24" @default.
• W1605753053 creator A5001015133 @default.
• W1605753053 creator A5002067050 @default.
• W1605753053 creator A5002075205 @default.
• W1605753053 creator A5039172045 @default.
• W1605753053 creator A5049905470 @default.
• W1605753053 creator A5060156953 @default.
• W1605753053 creator A5063351941 @default.
• W1605753053 creator A5070237845 @default.
• W1605753053 creator A5078658828 @default.
• W1605753053 creator A5090250933 @default.
• W1605753053 creator A5091793648 @default.
• W1605753053 date "2015-07-01" @default.
• W1605753053 modified "2023-09-27" @default.
• W1605753053 title "Impact of Exogenous Galectin-9 on Human T Cells" @default.
• W1605753053 cites W1492993345 @default.
• W1605753053 cites W1541131175 @default.
• W1605753053 cites W1541574343 @default.
• W1605753053 cites W1585589080 @default.
• W1605753053 cites W1586743471 @default.
• W1605753053 cites W167027881 @default.
• W1605753053 cites W1916286124 @default.
• W1605753053 cites W1949498377 @default.
• W1605753053 cites W1966193262 @default.
• W1605753053 cites W1968791512 @default.
• W1605753053 cites W1972073222 @default.
• W1605753053 cites W1973023339 @default.
• W1605753053 cites W1983206076 @default.
• W1605753053 cites W1983304896 @default.
• W1605753053 cites W1985543189 @default.
• W1605753053 cites W1985656418 @default.
• W1605753053 cites W1985997449 @default.
• W1605753053 cites W1989052616 @default.
• W1605753053 cites W1989488426 @default.
• W1605753053 cites W1993528700 @default.
• W1605753053 cites W1994299552 @default.
• W1605753053 cites W1997731331 @default.
• W1605753053 cites W2014392340 @default.
• W1605753053 cites W2015385085 @default.
• W1605753053 cites W2015493647 @default.
• W1605753053 cites W2016081852 @default.
• W1605753053 cites W2017107299 @default.
• W1605753053 cites W2035562653 @default.
• W1605753053 cites W2035808799 @default.
• W1605753053 cites W2036574174 @default.
• W1605753053 cites W2038064001 @default.
• W1605753053 cites W2038425480 @default.
• W1605753053 cites W2049652679 @default.
• W1605753053 cites W2055600777 @default.
• W1605753053 cites W2058380315 @default.
• W1605753053 cites W2063654126 @default.
• W1605753053 cites W2065100759 @default.
• W1605753053 cites W2070631889 @default.
• W1605753053 cites W2072772016 @default.
• W1605753053 cites W2074108502 @default.
• W1605753053 cites W2079025114 @default.
• W1605753053 cites W2084388859 @default.
• W1605753053 cites W2087186398 @default.
• W1605753053 cites W2090590534 @default.
• W1605753053 cites W2102013854 @default.
• W1605753053 cites W2102512885 @default.
• W1605753053 cites W2107777135 @default.
• W1605753053 cites W2108348830 @default.
• W1605753053 cites W2111077733 @default.
• W1605753053 cites W2112101426 @default.
• W1605753053 cites W2117156688 @default.
• W1605753053 cites W2129399184 @default.
• W1605753053 cites W2146796201 @default.
• W1605753053 cites W2152044035 @default.
• W1605753053 cites W2153919683 @default.
• W1605753053 cites W2157274127 @default.
• W1605753053 cites W2158751506 @default.
• W1605753053 cites W2163025939 @default.
• W1605753053 cites W2345968243 @default.
• W1605753053 doi "https://doi.org/10.1074/jbc.m115.661272" @default.
• W1605753053 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4505427" @default.
• W1605753053 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25947381" @default.
• W1605753053 hasPublicationYear "2015" @default.
• W1605753053 type Work @default.
• W1605753053 sameAs 1605753053 @default.
• W1605753053 citedByCount "47" @default.
• W1605753053 countsByYear W16057530532016 @default.
• W1605753053 countsByYear W16057530532017 @default.
• W1605753053 countsByYear W16057530532018 @default.
• W1605753053 countsByYear W16057530532019 @default.
• W1605753053 countsByYear W16057530532020 @default.
• W1605753053 countsByYear W16057530532021 @default.
• W1605753053 countsByYear W16057530532022 @default.
• W1605753053 countsByYear W16057530532023 @default.
• W1605753053 crossrefType "journal-article" @default.
• W1605753053 hasAuthorship W1605753053A5001015133 @default.
• W1605753053 hasAuthorship W1605753053A5002067050 @default.
• W1605753053 hasAuthorship W1605753053A5002075205 @default.
• W1605753053 hasAuthorship W1605753053A5039172045 @default.
• W1605753053 hasAuthorship W1605753053A5049905470 @default.
• W1605753053 hasAuthorship W1605753053A5060156953 @default.
• W1605753053 hasAuthorship W1605753053A5063351941 @default.

• next